Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
One-year long-term safety study of tapentadol prolonged release versus oxycodone controlled release in chronic pain
2006-003482-14Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Oct 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in chronic pain, osteoarthritis (OA) and lumbodynia (LBP) comparing Tapentadol prolonged release with Oxycodone controlled release (2 arms). Primary endpoints: Long-term safety profile of tapentadol prolonged release and Exposure target. Started Oct 2006; status: completed.
02
Drugs
tapentadoloxycodone
03
Conditions
chronic painosteoarthritis (OA)lumbodynia (LBP)
Beyond the preview
Go deeper on 2006-003482-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003482-14.